Keyword

relugolix

Description: An oral gonadotropin-releasing hormone receptor antagonist used to suppress sex hormones in conditions including prostate cancer.
Wikidata ID: wiki/Q21099000
OpenAlex ID: keywords/relugolix
2021 · Ayman Al-Hendy, Andrea S. Lukes, et al. · New England Journal of Medicine · 252
2021 · Nicolas Sayegh, Umang Swami, et al. · JCO Oncology Practice · 152
2023 · Nicholas A. Meanwell · Medicinal Chemistry Research · 88
2024 · Jacques Donnez, Hugh S. Taylor, et al. · Fertility and Sterility · 81
2015 · David B. MacLean, Hongliang Shi, et al. · The Journal of Clinical Endocrinology & Metabolism · 75
2024 · Anais Alonso, Kate Gunther, et al. · Current Opinion in Obstetrics & Gynecology · 71
2021 · Susan Dababou, Simone Garzon, et al. · Expert Opinion on Investigational Drugs · 68
2019 · Anthony Markham · Drugs · 66
2022 · Ayman Al-Hendy, Andrea S. Lukes, et al. · Obstetrics and Gynecology · 60
2022 · Eun-mi Yu, Jeanny B. Aragon-Ching · Expert Opinion on Pharmacotherapy · 51
2021 · Mohamed Ali, Mohamed Raslan, et al. · Expert Opinion on Drug Safety · 43
2021 · Filipe Cirne, Nazanin Aghel, et al. · European Heart Journal - Cardiovascular Pharmacotherapy · 43
Works count: 561
Citation count: 3,810
Year
Topic
Type